Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: July 2, 2006 (Second Quarter of Fiscal Year 2006)
Business Overview: Illumina develops, manufactures, and markets tools for the large-scale analysis of genetic variation and biological function, including genotyping systems (BeadArray, BeadChip), gene expression products, and oligonucleotide synthesis. The company operates in a single segment.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended July 2, 2006 |
Three Months Ended July 3, 2005 |
Six Months Ended July 2, 2006 |
Six Months Ended July 3, 2005 |
|---|---|---|---|---|
| Total Revenue | $41,577 | $15,824 | $70,679 | $30,972 |
| Net Income (Loss) | $6,768 | $(18,539) | $6,664 | $(19,774) |
| Operating Income (Loss) | $6,523 | $(18,546) | $5,982 | $(19,925) |
| Diluted EPS | $0.14 | $(0.46) | $0.14 | $(0.50) |
| Cash and Equivalents (End of Period) | $152,250 (as of July 2, 2006) | |||
| Operating Cash Flow (6 Months) | $17,263 | $(7,194) |
Margins (Six Months Ended July 2, 2006):
- Product Gross Margin: 67% (down from 68% in prior year period)
- Service Gross Margin: 67% (down from 75% in prior year period)
- Operating Margin: 8.5%
Debt and Liquidity:
- Total Current Assets: $199.3 million
- Total Current Liabilities: $34.9 million
- Long-term Debt: $0 (Current portion: $0.1 million)
- Stockholders' Equity: $186.7 million
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 163% year-over-year for the quarter and 128% for the six-month period. Product revenue grew 188% (quarter) and 141% (six months), driven by higher consumable sales (HumanHap300 and HumanHap550 BeadChips) and increased BeadStation and BeadLab instrument sales.
- Profitability Turnaround: The company reported net income of $6.8 million for the quarter and $6.7 million for the six months, compared to net losses of $18.5 million and $19.8 million in the prior year periods. This turnaround is primarily due to significant revenue growth and the absence of the $15.8 million in-process research and development (IPR&D) charge recorded in the prior year related to the CyVera acquisition.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses nearly doubled (98% increase for the quarter) due to stock-based compensation adoption (SFAS 123R), increased legal costs for the Affymetrix litigation, and expansion of the sales force. R&D expenses increased 17% (quarter) and 27% (six months), largely due to development of the acquired VeraCode technology.
- Cash Position: Cash and cash equivalents increased from $50.8 million to $152.3 million, driven by a public stock offering in May 2006 that generated $96.5 million in net proceeds and strong operating cash flow.
Guidance, Outlook, Risks, and Unusual Items
- Accounting Changes: The company adopted SFAS No. 123R (Share-Based Payment) on January 2, 2006, resulting in an incremental stock-based compensation expense of $3.3 million for the quarter and $6.5 million for the six months. This reduced net income per diluted share by $0.07 and $0.14, respectively.
- Legal Proceedings:
- Affymetrix Litigation: Affymetrix alleges patent infringement regarding BeadArray products. Trial is scheduled for October 16, 2006. The company expects substantial legal costs and notes that an unfavorable outcome could materially adversely affect operations.
- Dr. Anthony Czarnik: A former employee filed suit regarding inventorship and fraud. The court dismissed some counts in July 2006; the company is defending the remaining claims.
- Collaborations and Investments:
- Invitrogen: Collaboration for oligo sales continues; profits are split equally.
- deCODE genetics: New joint development agreement signed in May 2006 for diagnostic tests.
- Genizon BioSciences: Illumina purchased a $3.0 million secured convertible debenture. Approximately $3.0 million of revenue related to product shipments to Genizon has been deferred as a long-term liability due to "linked" transaction rules.
- Outlook: Management expects to continue incurring substantial costs for R&D and manufacturing scale-up. While profitable for the first half of 2006, the company cautions that quarterly results may fluctuate and that annual profitability for 2006 is not guaranteed due to the impact of SFAS 123R and increasing operating expenses.
Key Facts for Investor Verification
- Revenue Quality: Verify the sustainability of the 128% year-over-year revenue growth, specifically the mix of high-margin instruments versus consumables.
- Legal Exposure: Monitor the October 2006 trial date for the Affymetrix patent infringement suit, as an injunction or significant damages could materially impact the business.
- Deferred Revenue: Confirm the treatment of the $3.0 million deferred revenue related to the Genizon BioSciences transaction and the conditions required for its recognition.
- Stock-Based Compensation: Assess the full-year impact of SFAS 123R, estimated at an additional $13.0 million to $15.0 million in expenses for 2006, on future profitability.
- Manufacturing Capacity: Verify the company's ability to meet demand given the tenfold increase in BeadChip manufacturing capacity and the reliance on single-source vendors for key components.